Compare ImmunityBio Inc. Common Stock (IBRX) vs Public Service Enterprise Group Incorporated Common Stock (PEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Public Service Enterprise Group Incorporated Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.39B), while Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 3.4× ImmunityBio Inc. Common Stock's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and Public Service Enterprise Group Incorporated Common Stock for 0 Days on average.
| IBRX | PEG | |
|---|---|---|
Market Cap | $10.39B | $35.12B |
Volume | 11,509,049 | 4,400,164 |
Sector | Health | Utilities |
52-Week High | $11.55 | $86.95 |
52-Week Low | $1.98 | $66.56 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.84B | $59.61B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →
